<DOC>
	<DOC>NCT00150423</DOC>
	<brief_summary>To evaluate the safety and efficacy of pregabalin in patients with painful diabetic peripheral neuropathy.</brief_summary>
	<brief_title>To Evaluate the Safety and Efficacy of Pregabalin in Patients With Painful Diabetic Peripheral Neuropathy.</brief_title>
	<detailed_description />
	<mesh_term>Pain</mesh_term>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<criteria>Must have met the inclusion criteria for the preceding doubleblind BID study in painful diabetic peripheral neuropathy Must have received pregabalin/placebo under doubleblind conditions for a minimum of 3 weeks. Patients may not participate if they experienced a serious adverse event during the preceding doubleblind BID study which was determined to be related to the study medication.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2006</verification_date>
</DOC>